Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people - PubMed (original) (raw)
Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people
Kenneth Rockwood et al. Arch Neurol. 2002 Feb.
Abstract
Background: Recent reports suggest a possibly protective effect for statins in patients with Alzheimer disease. This association could be due to indication bias, i.e., people who elect to take lipid-lowering agents (LLAs) may be healthier than those who do not, so that it may be these other health factors that explain their lower risk of dementia.
Objectives: To examine the association between the use of LLAs and dementia, adjusting for other markers of health, and to investigate factors associated with LLA use.
Design: A cohort study of LLA use and a case-control study of dementia in relation to LLA use, in a secondary analysis of the Canadian Study of Health and Aging.
Setting: A nationally representative population-based survey of Canadians 65 years and older.
Participants: To examine features associated with statin use, we evaluated data on 2305 people for whom health information, drug use, and cognitive status were known. To examine the relationship between LLA use and dementia, we selected incident cases of dementia (n = 492, of whom 326 had Alzheimer disease) that occurred between the first and second waves of the study. Control subjects were 823 persons examined during the first and second phases of the Canadian Study of Health and Aging who had no cognitive impairment.
Results: Use of LLAs was significantly (P<.001) more common in younger (65-79 years) than in older (> or = 80 years) people. It was not associated with other factors indicating a healthy lifestyle, but was associated with a history of smoking and hypertension. Use of statins and other LLAs reduced the risk of Alzheimer disease in subjects younger than 80 years, an effect that persisted after adjustment for sex, educational level, and self-rated health (odds ratio, 0.26; 95% confidence interval, 0.08-0.88). There was no significant effect in subjects 80 years and older.
Conclusions: While the possibility of indication bias in the original observations cannot be excluded, it was not demonstrated in LLA use in this study. Lipid-lowering agent use was associated with a lower risk of dementia, and specifically of Alzheimer disease, in those younger than 80 years. Further research is warranted.
Similar articles
- Statins and the risk of dementia.
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Jick H, et al. Lancet. 2000 Nov 11;356(9242):1627-31. doi: 10.1016/s0140-6736(00)03155-x. Lancet. 2000. PMID: 11089820 - Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status.
Rockwood K, Howlett S, Fisk J, Darvesh S, Tuokko H, Hogan DB, Wolfson C, McDowell I. Rockwood K, et al. Neuroepidemiology. 2007;29(3-4):201-7. doi: 10.1159/000111583. Epub 2007 Nov 27. Neuroepidemiology. 2007. PMID: 18043005 - APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.
Dufouil C, Richard F, Fiévet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alpérovitch A. Dufouil C, et al. Neurology. 2005 May 10;64(9):1531-8. doi: 10.1212/01.WNL.0000160114.42643.31. Neurology. 2005. PMID: 15883313 - The risk of dementia in relation to statins and other lipid lowering agents.
Rockwood K, Darvesh S. Rockwood K, et al. Neurol Res. 2003 Sep;25(6):601-4. doi: 10.1179/016164103101202039. Neurol Res. 2003. PMID: 14503013 Review. - The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease.
McGuinness B, Todd S, Passmore P, Bullock R. McGuinness B, et al. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004034. doi: 10.1002/14651858.CD004034.pub2. Cochrane Database Syst Rev. 2006. PMID: 16625595 Updated. Review.
Cited by
- Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits.
Tong XK, Lecrux C, Rosa-Neto P, Hamel E. Tong XK, et al. J Neurosci. 2012 Apr 4;32(14):4705-15. doi: 10.1523/JNEUROSCI.0169-12.2012. J Neurosci. 2012. PMID: 22492027 Free PMC article. - Cumulative effect of simvastatin, L-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer's disease.
Degrush E, Shazeeb MS, Drachman D, Vardar Z, Lindsay C, Gounis MJ, Henninger N. Degrush E, et al. Alzheimers Res Ther. 2022 Sep 17;14(1):134. doi: 10.1186/s13195-022-01076-7. Alzheimers Res Ther. 2022. PMID: 36115980 Free PMC article. - Multiplex biomarkers in blood.
Gupta VB, Sundaram R, Martins RN. Gupta VB, et al. Alzheimers Res Ther. 2013 Jun 25;5(3):31. doi: 10.1186/alzrt185. eCollection 2013. Alzheimers Res Ther. 2013. PMID: 23795953 Free PMC article. Review. - Statins and cognitive function: an updated review.
Chatterjee S, Krishnamoorthy P, Ranjan P, Roy A, Chakraborty A, Sabharwal MS, Ro R, Agarwal V, Sardar P, Danik J, Giri JS, DeGoma EM, Kumbhani DJ. Chatterjee S, et al. Curr Cardiol Rep. 2015 Feb;17(2):4. doi: 10.1007/s11886-014-0559-3. Curr Cardiol Rep. 2015. PMID: 25618304 Review. - Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review.
Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Ligthart SA, et al. Vasc Health Risk Manag. 2010 Sep 7;6:775-85. doi: 10.2147/vhrm.s7343. Vasc Health Risk Manag. 2010. PMID: 20859546 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical